Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 69819-86-9, Zinapar, Zio-101, Dmas(iii)g, Sp-02l, Zio 101

Molecular Formula

C₁₂H₂₂AsN₃O₆S

Molecular Weight

411.31 g/mol

InChI Key

JGDXFQORBMPJGR-YUMQZZPRSA-N

FDA UNII

9XX54M675G

Darinaparsin is a small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.

1 2D Structure

Darinaparsin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

2.1.2 InChI

InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1

2.1.3 InChI Key

JGDXFQORBMPJGR-YUMQZZPRSA-N

2.1.4 Canonical SMILES

C[As](C)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N

2.1.5 Isomeric SMILES

C[As](C)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N

2.2 Other Identifiers

2.2.1 UNII

9XX54M675G

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Clarinaparsin

2. Dimethylarsinous Glutathione

3. Dmas(iii)g

4. Dmas(iii)sg

5. S-(dimethylarsino)-glutathione

6. S-(dimethylarsino)glutathione

7. S-dimethylarsino-glutathione

8. Zio 101

9. Zio-101

10. Zio101

2.3.2 Depositor-Supplied Synonyms

1. 69819-86-9

2. Zinapar

3. Zio-101

4. Dmas(iii)g

5. Sp-02l

6. Zio 101

7. 9xx54m675g

8. Glycine, L-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl-

9. Clarinaparsin

10. (s)-2-amino-5-(((r)-1-((carboxymethyl)amino)-3-((dimethylarsino)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic Acid

11. Darinaparsin [usan]

12. Dmas(iii)sg

13. Darinaparsin [usan:inn]

14. Dimethylarsinous Glutathione

15. S-dimethylarsino-glutathione

16. S-(dimethylarsino)glutathione

17. S-(dimethylarsino)-glutathione

18. Unii-9xx54m675g

19. Zio101

20. Sglu1

21. Darinaparsin [mi]

22. S-dimethylarsinoglutathione

23. Darinaparsin (jan/usan)

24. Darinaparsin [inn]

25. Darinaparsin [jan]

26. S-dimethylarsino Glutathione

27. Darinaparsin [who-dd]

28. Schembl411358

29. Sp02

30. Chembl3247378

31. Chebi:94295

32. Zio-101-c

33. Dtxsid80220108

34. Bcp15637

35. Db06179

36. Hy-14943

37. Zio 101; Zio101; Zio-101

38. D08898

39. Brd-k35723520-001-01-0

40. Q27166111

41. Glycine, L-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl

42. L-gamma-glutamyl-s-(dimethylarsanyl)-l-cysteinylglycine

43. L-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl-glycine

44. Glycine, L-.gamma.-glutamyl-s-(dimethylarsino)-l-cysteinyl-

45. (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic Acid

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₁₂H₂₂AsN₃O₆S
Molecular Weight	411.31 g/mol
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	11
Exact Mass	411.044526 g/mol
Monoisotopic Mass	411.044526 g/mol
Topological Polar Surface Area	184 Å²
Heavy Atom Count	23
Formal Charge	0
Complexity	449
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer.

Drugs in Development